Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.75 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 3/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17180570 | 1.00 | GLP1R (0.75) | GLP1RLPAR3LPAR1TLR2SIRT2 | |
| SCHEMBL15259274 | 0.92 | GLP1R (0.75) | GLP1RLPAR3LPAR1TLR2SIRT2 | |
| SCHEMBL17180569 | 0.92 | GLP1R (0.75) | GLP1RLPAR3LPAR1TLR2SIRT2 | |
| SCHEMBL14438806 | 0.88 | GLP1R (0.70) | GLP1RLPAR3LPAR1TLR2SIRT2 | |
| SCHEMBL15259287 | 0.88 | GLP1R (0.70) | GLP1RLPAR3LPAR1TLR2SIRT2 | |
| SCHEMBL17189428 | 0.88 | GLP1R (0.70) | GLP1RLPAR3LPAR1TLR2SIRT2 | |
| SCHEMBL15084768 | 0.88 | GLP1R (0.65) | GLP1RLPAR3LPAR1TLR2SIRT2 | |
| SCHEMBL22478893 | 0.87 | GLP1R (0.68) | GLP1RLPAR3LPAR1TLR2NOD1 | |
| SCHEMBL15257828 | 0.87 | GLP1R (0.68) | GLP1RLPAR3LPAR1TLR2SIRT2 | |
| SCHEMBL15259273 | 0.86 | GLP1R (0.67) | GLP1RLPAR3LPAR1TLR2SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203058-A1 | Novel Glp-1 Derivatives | NOVO NORDISK A/S (DK) | 2007-08-30 | — | — | US | disclosed |
| US-20070203058-A1 | Novel Glp-1 Derivatives | NOVO NORDISK A/S (DK) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203058-A1 | Novel Glp-1 Derivatives | GLP1R, GIPR, NPY4R | GLP1R 1/4885LPAR3 226/4885LPAR1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.